ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that
Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences:
A live audio webcast of each presentation can be accessed under “Events and Presentations” in the Investors section of the
Company’s website at www.aviragentherapeutics.com. An archived replay of the webcast will be available for 30 days
after the live event concludes.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat
infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three
product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus upper (HRV)
respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 mcolonnese@aviragentherapeutics.com Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 beth@sternir.com
